Cargando…
Dramatic response of aneurysmal bone cyst to denosumab: Case report and literature review
Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor‐kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.
Autores principales: | Fadavi, Pedram, Arefpour, Amir Mohammad, Hariri, Ramyar, Vasheghani, Maryam, Garousi, Maryam, Taghizadeh‐Hesary, Farzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548816/ https://www.ncbi.nlm.nih.gov/pubmed/34745616 http://dx.doi.org/10.1002/ccr3.4993 |
Ejemplares similares
-
Dramatic response to radiation of a sinus melanoma: A case report
por: Garousi, Maryam, et al.
Publicado: (2023) -
Serum Ferritin, Vitamin D and Pathological Factors in Breast Cancer Patients
por: Fadavi, Pedram, et al.
Publicado: (2021) -
Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review
por: Alhumaid, Ibrahim, et al.
Publicado: (2019) -
Aneurysmal bone cyst: results of an off label treatment with Denosumab
por: Dürr, Hans Roland, et al.
Publicado: (2019) -
The uterine adenosarcoma with postoperative residual in a woman treated by total abdominal hysterectomy/bilateral salpingo‐oophorectomy: A case report and review of literature
por: Fadavi, Pedram, et al.
Publicado: (2023)